US District Court Denies Thermi's Motions to Dismiss Viveve Patent Infringement Suit
SUNNYVALE, CA -- (Marketwired) -- 04/25/17 -- Viveve Medical, Inc.'s (NASDAQ: VIVE) wholly-owned subsidiary, Viveve, Inc. ("Viveve"), a medical technology company focused on women's health, today announced that the U.S. District Court for the Eastern District of Texas has denied motions to dismiss the patent infringement suit filed by Viveve against ThermiGen, LLC, ThermiAesthetics, LLC, and Dr. Red Alinsod (collectively "Defendants"). The lawsuit seeks redress for the Defendants' alleged unauthorized use of Viveve's patented technology.
The patent infringement lawsuit was filed by Viveve on October 16, 2016 and is intended to protect Viveve's significant investment in the development of its technology. In this lawsuit, Viveve is pursuing all available remedies, including an injunction to prevent the Defendants from selling or promoting products and treatment methods that infringe on U.S. Patent No. 8,961,511 entitled, "Vaginal Remodeling Device and Methods", which is held by Viveve.
Viveve Medical, Inc. is a women's health and wellness company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System, that delivers the GENEVEVE™ treatment, incorporates cryogen-cooled, monopolar radiofrequency (CMRF) to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in one 30-minute in-office session.
In the United States, the Viveve System is cleared by the FDA for general surgical procedures for electrocoagulation and hemostasis. Consistent with approvals in many countries internationally, Viveve is currently in the process of submitting an IDE to the FDA to conduct a pivotal study on use of the device in the United States for improvement in sexual function. For more information visit Viveve's website at www.viveve.com.
Safe Harbor Statement
All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Viveve is a registered trademark of Viveve, Inc.
Geneveve is a trademark of Viveve, Inc.
Investor Relations contact:
Amato and Partners, LLC
90 Park Avenue, 17th Floor
New York, NY 10016
Berry & Company Public Relations
Source: Viveve Medical, Inc.
Released April 25, 2017